In an early trial, personalized cancer vaccines reduced the risk of recurrence or death among people with late-stage melanoma by 44%.
April 17, 2023 – Researchers this past weekend unveiled clinical trial results for a “major breakthrough” that would personalize cancer treatment.
The treatment approach uses mRNA vaccine technology that became well-known for its use in COVID-19 vaccines. The personalized cancer shots are created using information from an individual person’s tumor. The vaccines for people involved in the melanoma study were customized in 34 ways that were specific to a person’s tumor.
Among people in the vaccine group, 78.6% were alive and had not had a cancer recurrence 18 months later. In the Keytruda-only group, 62.2% were alive and had not had a recurrence. The metric is called “recurrence-free survival” among cancer researchers.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Personalized vaccine for melanoma may stave off cancer’s returnSmall trial offers first clinical evidence that a tailored vaccine works and tests of others also look promising
Weiterlesen »
44% say America would be ‘worse off’ without the Bible, but usage has fallen: SurveyAbout 44% of Americans say the nation would be worse off without the Bible, the American Bible Society reported in the first installment of its 2023 “State of the Bible” survey.
Weiterlesen »
Moderna Shows Progress Toward Cancer VaccinesModerna’s mRNA cancer vaccine helped prevent relapse for melanoma patients, results from a mid-stage trial showed, demonstrating progress in the pursuit of shots to ward off cancer by jump-starting the immune system
Weiterlesen »
Moderna, Merck Show Progress Toward Cancer VaccinesModerna’s mRNA cancer vaccine helped prevent relapse for people with high-risk melanoma in a mid-stage trial, some of the strongest evidence yet that such vaccines could benefit patients
Weiterlesen »
Moderna cancer vaccine with Merck's Keytruda delays return of deadly skin cancerAn experimental mRNA vaccine developed by Moderna Inc combined with Merck & Co's blockbuster immunotherapy Keytruda cut the risk of death or recurrence of the most deadly skin cancer by 44% compared Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.
Weiterlesen »